Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model-Reference-Cited by-同舟云学术

Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection model

Published:2022-05 Issue:5 Volume:28 Page:635-642
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Fujita Kiyoko,Takata Iichiro,Yoshida Ippei,Honma Yusuke,Okumura Hirotoshi^ORCID,Otake Katsumasa,Takashima Hajime^ORCID,Sugiyama Hiroyuki^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference37 articles.

1. Multidrug resistant gram-negative bacteria in community-acquired pneumonia;Cillóniz;Crit Care,2019

2. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options;Cerceo;Microb Drug Resist,2016

3. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study;Temkin;Lancet Global Health,2018

4. Analysis of the clinical antibacterial and antituberculosis pipeline;Theuretzbacher;Lancet Infect Dis,2019

5. A complete pathway model for lipid A biosynthesis in Escherichia coli;Emiola;PLoS One,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii;Nature Microbiology;2024-04-22

2. TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on In Vitro Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae;Microbiology Spectrum;2022-06-29